ArticleEClinicalMedicine2023

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial.

Alexandra Compagnucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.